Skip to main content
FDA expands use of GSK's Arnuity Ellipta for pediatric asthma
5/22/2018

GlaxoSmithKline's Arnuity Ellipta, or fluticasone furoate, was approved by the FDA as a maintenance treatment for children with asthma who are at least 5 years old. The drug was previously approved for use among patients ages 12 and older.

Full Story: